Yes the price per indication would be different as the number of cycles can be different, but it is rare outside of sarcoma to go past 4 cycles these days because of the cardiotoxicity risk.
The estimate in the Triangle report is pretty conservative - to give you an example, G1 Therapeutics' Cosela has a list price of $US32K per chemo cycle and it provides no anticancer efficacy, just some (limited) protection from myleosupression.
Yes the price per indication would be different as the number of...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
-0.100(5.76%) |
Mkt cap ! $278.5M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.71 | $1.64 | $205.3K | 123.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1526 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 234 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |